Osteocalcin Antikörper (AA 2-32)

Produktnummer ABIN3030174

Produktdetails anti-Osteocalcin Antikörper

Target: Osteocalcin (BGLAP)

Bindungsspezifität: AA 2-32

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser Osteocalcin Antikörper ist unkonjugiert

Applikation: ELISA, Immunohistochemistry (IHC), Western Blotting (WB)

Aufreinigung: Purified

Immunogen: A portion of amino acids 2-32 from the human protein was used as the immunogen for this Osteocalcin antibody.

Isotyp: Ig Fraction

Anwendungsinformationen

Applikationshinweise: Titration of the Osteocalcin antibody may be required due to differences in protocols and secondary/substrate sensitivity.\. Western blot: 1:1000,IHC (Paraffin): 1:50-1:100

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: In 1X PBS, pH 7.4, with 0.09 % sodium azide

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C

Informationen zur Lagerung: Aliquot the Osteocalcin antibody and store frozen at -20°C or colder. Avoid repeated freeze-thaw cycles.

Details zu Osteocalcin

Target: Osteocalcin (BGLAP)

Andere Bezeichnung: Osteocalcin (BGLAP Produkte)

Hintergrund: Prior to the formation of calcified bone, noncollagenous proteins form in the extracellular bone matrix. Gamma-carboxyglutamic acid residues are formed by vitamin K, vitamin-D regulated calcium binding proteins containing residues of Gla. These residues are essential for the binding of calcium and constitue 1-2 % of total bone protein. Osteocalcin itself binds strongly to apatite and calcium. Production of osteocalcin is expressed late in normal bone development and is characteristic of mature osteoblasts. Regular osteocalcin production has been shown to be linked to the p53 tumor suppressor gene. The p53 gene undergoes rearrangement in a high percentage of osteosarcomas, resulting in loss of its expression. The loss of p53 regulation inhibits further osteocalcin production. The absence of end-point differentiation in bone due to p53 rearrangements and lack of osteocalcin production may contribute to the maintenance of the tumorigenic phenotype in osteosarcomas.

UniProt: P02818